Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status.

Drug metabolism and disposition: the biological fate of chemicals - 1 Oct 2001

Kosuge K, Jun Y, Watanabe H, Kimura M, Nishimoto M, Ishizaki T, Ohashi K

Abstract excerpt

Diazepam is metabolized by CYP2C19 and CYP3A4 in the liver. CYP2C19 shows genetic polymorphism associated with the poor metabolizer (PM) and extensive metabolizer (EM) phenotypes. The aim of this study was to assess the effect of diltiazem, a CYP3A4 inhibitor, on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Thirteen healthy volunteers (eight EMs and five PMs) were given...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme Inhibitors

Share to Diazepam

Share to Drug Interactions

Share to Mixed Function Oxygenases

Source

Identifiers

PMID: 11560871

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status.PMID 11560871Read ↗

Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam.Semantic proximity Read ↗

CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia.Semantic proximity Read ↗

The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.Semantic proximity Read ↗

Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepinesSemantic proximity Read ↗

Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects.Semantic proximity Read ↗

Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem.Semantic proximity Read ↗

The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype.Semantic proximity Read ↗

Intravenous diazepam application in a departmental convulsive status epilepticus protocol with CYP2C19 polymorphisms: a pediatric prospective cohort study.Semantic proximity Read ↗

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.Semantic proximity Read ↗

Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.Semantic proximity Read ↗

Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.Semantic proximity Read ↗

Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.